USPTO 2015–2025 USPTO PatentsView US Corporation

Fibralign Corporation

USPTO PatentsView assignee record - 7 granted patents across 13 technology areas, active 2017–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES;).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

19.3

Avg claims per patent

-25%

5-year filing velocity

The verdict

Fibralign holds 7 US patents across 13 technology areas, rank #35,355 of 50,000 tracked assignees.

#35,355
of 50,000 US assignees by volume: Top 55%
by Innovation Score (33.7/100): 19.3
avg claims per patent: -25%
filing velocity, last 5 yrs

Portfolio overview

Fibralign Corporation has been granted 7 US utility patents between 2017 and 2022, placing Fibralign Corporation at rank #35,355 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.3 claims per patent with primary concentration in A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES;). As a US Corporation, Fibralign Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Fibralign sits between Feldan Bio Inc. (7 patents, rank #35,351) and Finzelberg Gmbh & Co. KG (7 patents, rank #35,359) - the closest US assignees by grant volume. The composite Innovation Score of 33.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 4 in the 2015–2019 window, a -25% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Fibralign Corporation's 19.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 13 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Fibralign Corporation against peers pursuing similar technology classes.

Feldan Bio

7
Fennec Pharmaceut…

7
Fetch Rewards

7
Figpin Collect Aw…

7
Fibria Celulose S…

7
Filnex

7
Finatec Holding

7
Finzelberg & KG

7
Fibralign ◀

7

What this shows Fibralign holds 7 patents at rank #35,355, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Fibralign

By rank, the assignees closest to #35,355 in granted patent volume.

Leaders in A61L (Methods OR Apparatus FOR Sterilising Materials OR Objects…)

Other assignees with the most granted patents in Fibralign's primary technology class.

Fibralign's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

34 Top 55% higher than 45% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Fibralign Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	14.3%
2018	2	28.6%
2019	1	14.3%
2020	1	14.3%
2021	1	14.3%
2022	1	14.3%

Which technologies does Fibralign Corporation patent most?

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 6

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 3

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 3

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 2

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 2

D01F - CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS 2

D01D - MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 1

D04H - MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL ; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION 1

C07K - PEPTIDES 1

D10B - INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES 1

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 1

Top 13 of 13 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#35,355

Across all tracked assignees

Innovation Score

33.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Fibralign Corporation hold?

Fibralign Corporation holds 7 US granted patents filed between 2017 and 2022, spanning 13 technology areas.

What is Fibralign Corporation's Innovation Score?

Fibralign Corporation has an Innovation Score of 33.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Fibralign Corporation focus on?

Fibralign Corporation's top technology area is A61L (METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES) with 6 patents. The company has filed patents in 13 CPC subclasses total.

Is Fibralign Corporation's patent filing rate increasing or decreasing?

Fibralign Corporation's recent filing velocity is -25% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Fibralign Corporation's patents?

Fibralign Corporation's patents average 19.3 claims each. This falls within the standard range, providing solid legal coverage.

How is the Fibralign Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Fibralign's 7 grants land it in the top 55% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Fibralign ranks #35,355 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61L - see who else leads that technology area. A61L leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.